JP2016535773A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535773A5 JP2016535773A5 JP2016552219A JP2016552219A JP2016535773A5 JP 2016535773 A5 JP2016535773 A5 JP 2016535773A5 JP 2016552219 A JP2016552219 A JP 2016552219A JP 2016552219 A JP2016552219 A JP 2016552219A JP 2016535773 A5 JP2016535773 A5 JP 2016535773A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- immediate release
- oral dosage
- cellulose
- abuse deterrent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000009032 substance abuse Diseases 0.000 claims 34
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 33
- 239000006186 oral dosage form Substances 0.000 claims 32
- 229920000642 polymer Polymers 0.000 claims 21
- 239000008186 active pharmaceutical agent Substances 0.000 claims 13
- 239000002552 dosage form Substances 0.000 claims 13
- 229920002678 cellulose Polymers 0.000 claims 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 9
- 229920002125 Sokalan® Polymers 0.000 claims 9
- 229920001577 copolymer Polymers 0.000 claims 9
- 239000001913 cellulose Substances 0.000 claims 8
- 229960001631 carbomer Drugs 0.000 claims 7
- 239000011159 matrix material Substances 0.000 claims 7
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 6
- 229920002472 Starch Polymers 0.000 claims 6
- 229940032147 starch Drugs 0.000 claims 6
- 235000019698 starch Nutrition 0.000 claims 6
- 239000008107 starch Substances 0.000 claims 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 5
- 239000011258 core-shell material Substances 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 4
- 229920000609 methyl cellulose Polymers 0.000 claims 4
- 239000001923 methylcellulose Substances 0.000 claims 4
- 235000010981 methylcellulose Nutrition 0.000 claims 4
- 229920002401 polyacrylamide Polymers 0.000 claims 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 3
- 239000001856 Ethyl cellulose Substances 0.000 claims 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims 3
- 229920001249 ethyl cellulose Polymers 0.000 claims 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 3
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 claims 2
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical compound CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 claims 2
- LYRSLMWAHYTKIG-UHFFFAOYSA-N 3-(1h-inden-1-yl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C2C3=CC=CC=C3C=C2)=C1 LYRSLMWAHYTKIG-UHFFFAOYSA-N 0.000 claims 2
- 244000215068 Acacia senegal Species 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims 2
- 229920001817 Agar Polymers 0.000 claims 2
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims 2
- 229920002284 Cellulose triacetate Polymers 0.000 claims 2
- 244000303965 Cyamopsis psoralioides Species 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 229920000084 Gum arabic Polymers 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims 2
- 235000010489 acacia gum Nutrition 0.000 claims 2
- 239000000205 acacia gum Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000008272 agar Substances 0.000 claims 2
- 235000010419 agar Nutrition 0.000 claims 2
- 235000010443 alginic acid Nutrition 0.000 claims 2
- 229920000615 alginic acid Polymers 0.000 claims 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 229920003086 cellulose ether Polymers 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 2
- 229960000920 dihydrocodeine Drugs 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 239000004084 narcotic analgesic agent Substances 0.000 claims 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical group C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 241000416162 Astragalus gummifer Species 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 1
- 229920000569 Gum karaya Polymers 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 241000934878 Sterculia Species 0.000 claims 1
- 240000001058 Sterculia urens Species 0.000 claims 1
- 235000015125 Sterculia urens Nutrition 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 239000007891 compressed tablet Substances 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- 239000002895 emetic Substances 0.000 claims 1
- 229960000450 esketamine Drugs 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 235000010494 karaya gum Nutrition 0.000 claims 1
- 239000000231 karaya gum Substances 0.000 claims 1
- 229940039371 karaya gum Drugs 0.000 claims 1
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 235000010487 tragacanth Nutrition 0.000 claims 1
- 239000000196 tragacanth Substances 0.000 claims 1
- 229940116362 tragacanth Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898207P | 2013-10-31 | 2013-10-31 | |
| US61/898,207 | 2013-10-31 | ||
| US14/333,986 | 2014-07-17 | ||
| PCT/US2014/047014 WO2015065547A1 (en) | 2013-10-31 | 2014-07-17 | Immediate release abuse-deterrent granulated dosage forms |
| USPCT/US2014/047014 | 2014-07-17 | ||
| US14/333,986 US20150118300A1 (en) | 2013-10-31 | 2014-07-17 | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| USPCT/US2014/054061 | 2014-09-04 | ||
| PCT/US2014/054061 WO2015065586A1 (en) | 2013-10-31 | 2014-09-04 | Immediate release abuse-deterrent granulated dosage forms |
| US14/477,354 | 2014-09-04 | ||
| US14/477,354 US20150118301A1 (en) | 2013-10-31 | 2014-09-04 | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| US14/484,793 US20150118295A1 (en) | 2013-10-31 | 2014-09-12 | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| US14/484,793 | 2014-09-12 | ||
| PCT/US2014/062887 WO2015066172A1 (en) | 2013-10-31 | 2014-10-29 | Immediate release abuse-deterrent granulated dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535773A JP2016535773A (ja) | 2016-11-17 |
| JP2016535773A5 true JP2016535773A5 (enExample) | 2017-12-07 |
| JP6659925B2 JP6659925B2 (ja) | 2020-03-04 |
Family
ID=51263565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552219A Active JP6659925B2 (ja) | 2013-10-31 | 2014-10-29 | 即放性乱用抑止性剤形 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US20150118300A1 (enExample) |
| JP (1) | JP6659925B2 (enExample) |
| KR (1) | KR102363573B1 (enExample) |
| CN (1) | CN105682647A (enExample) |
| AU (1) | AU2014342412B2 (enExample) |
| CL (1) | CL2016001031A1 (enExample) |
| HK (1) | HK1223856A1 (enExample) |
| MX (1) | MX384376B (enExample) |
| PE (1) | PE20160606A1 (enExample) |
| WO (2) | WO2015065547A1 (enExample) |
| ZA (1) | ZA201604451B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| CN102014877B (zh) | 2008-01-25 | 2017-06-06 | 格吕伦塔尔有限公司 | 药物剂型 |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| JP2012533585A (ja) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 酸化感受性オピオイドのための不正使用防止剤形 |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| NZ608865A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising an anionic polymer |
| PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
| MX348491B (es) | 2011-07-29 | 2017-06-15 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US12208068B2 (en) * | 2013-12-31 | 2025-01-28 | Pharmapotheca A Inc. | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms |
| WO2015120201A1 (en) | 2014-02-05 | 2015-08-13 | Kashiv Pharma, Llc | Abuse-resistant drug formulations with built-in overdose protection |
| AU2015237721B2 (en) * | 2014-03-26 | 2018-04-26 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US20180185352A1 (en) * | 2015-06-09 | 2018-07-05 | KVK-Tech, Inc. | Abuse deterrent pharmaceutical compositions |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| GB201520007D0 (en) * | 2015-11-12 | 2015-12-30 | Sensidose Ab | Compacted powder |
| EP3442940A1 (en) | 2016-04-11 | 2019-02-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
| WO2018044895A1 (en) | 2016-08-29 | 2018-03-08 | Cima Labs Inc. | Immediate release dosage forms with abuse deterrence and alcohol resistance |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
| JP7125436B2 (ja) | 2017-06-23 | 2022-08-24 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッド | 乱用抑止経口固体投与形態 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10532869B2 (en) | 2017-11-01 | 2020-01-14 | Eighty Eight Pharma, Inc. | Device for deterring abuse of drugs |
| CA3117809A1 (en) * | 2018-11-01 | 2020-05-07 | Molecular Infusions, Llc | Polymer-based oral cannabinoid and/or terpene formulations |
| BR112021014435A2 (pt) * | 2019-01-25 | 2021-09-21 | Nouryon Chemicals International B.V. | Cápsulas esféricas compreendendo um invólucro polimérico que circunda um núcleo oco, e processo para preparar cápsulas esféricascápsulas esféricas compreendendo um invólucro polimérico que circunda um núcleo oco, e processo para preparar cápsulas esféricas |
| TWI744858B (zh) * | 2019-04-12 | 2021-11-01 | 財團法人醫藥工業技術發展中心 | 治療精神疾病之控釋藥物組合物和方法 |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| US20220202742A1 (en) * | 2019-05-07 | 2022-06-30 | Clexio Biosciences Ltd. | Dosage forms for preventing drug-facilitated assault |
| US20220062200A1 (en) * | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11071739B1 (en) | 2020-09-29 | 2021-07-27 | Genus Lifesciences Inc. | Oral liquid compositions including chlorpromazine |
| US20230414514A1 (en) * | 2022-06-22 | 2023-12-28 | Purdue Research Foundation | Formulation to deter abuse of drugs by smoking |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5248669A (en) | 1991-12-17 | 1993-09-28 | Samir Amer | Inhibition of anoxia or hypoxia-induced, endothelium-mediated vasospasm with avermectins |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5968551A (en) | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| IL110014A (en) | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US6210714B1 (en) | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
| GB9401894D0 (en) * | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| DE4413350A1 (de) | 1994-04-18 | 1995-10-19 | Basf Ag | Retard-Matrixpellets und Verfahren zu ihrer Herstellung |
| US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
| US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| GB9519363D0 (en) | 1995-09-22 | 1995-11-22 | Euro Celtique Sa | Pharmaceutical formulation |
| US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
| CN100475210C (zh) | 1996-03-08 | 2009-04-08 | 尼科梅德丹麦有限公司 | 改进释放的多单位剂量组合物 |
| US20020110595A1 (en) | 1996-06-28 | 2002-08-15 | Basf Corporation | Slow release pharmaceutical compositions |
| US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
| BE1011045A3 (fr) | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| US6607751B1 (en) | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
| US20040028735A1 (en) | 1997-11-14 | 2004-02-12 | Unchalee Kositprapa | Pharmaceutical formulation |
| US6251430B1 (en) | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
| US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| SE9803239D0 (sv) | 1998-09-24 | 1998-09-24 | Diabact Ab | Composition for the treatment of acute pain |
| US6033686A (en) | 1998-10-30 | 2000-03-07 | Pharma Pass Llc | Controlled release tablet of bupropion hydrochloride |
| EP2020229A1 (en) | 1998-11-02 | 2009-02-04 | Elan Pharma International Limited | Multiparticulate modified release composition |
| DE19901687B4 (de) | 1999-01-18 | 2006-06-01 | Grünenthal GmbH | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung |
| PE20001396A1 (es) | 1999-01-18 | 2000-12-23 | Gruenenthal Chemie | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista |
| AU780397B2 (en) | 1999-02-03 | 2005-03-17 | Powderject Research Limited | Hydrogel particle formulations |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6680071B1 (en) | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
| ATE258417T1 (de) | 1999-07-02 | 2004-02-15 | Cognis Iberia Sl | Mikrokapseln - i |
| EP1064913B1 (de) | 1999-07-02 | 2005-09-14 | Cognis IP Management GmbH | Mikrokapseln - III |
| DE19932603A1 (de) | 1999-07-13 | 2001-01-25 | Gruenenthal Gmbh | Wirkstoffhaltiger Mehrschichtfilm aus in situ vernetzten hydrophilen Polymeren |
| US6500459B1 (en) | 1999-07-21 | 2002-12-31 | Harinderpal Chhabra | Controlled onset and sustained release dosage forms and the preparation thereof |
| US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| SE9903236D0 (sv) | 1999-09-10 | 1999-09-10 | Astra Ab | Method to obtain microparticles |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| US6708822B1 (en) | 1999-11-30 | 2004-03-23 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| ATE293977T1 (de) | 1999-12-08 | 2005-05-15 | Pharmacia Corp | Nanopartikelzusammensetzungen enthaltend eplerenon |
| SI1299104T1 (sl) | 2000-02-08 | 2009-10-31 | Euro Celtique Sa | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| EP1276470B1 (en) * | 2000-04-20 | 2007-05-02 | Novartis AG | Taste masking coating composition |
| US6419954B1 (en) | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| DE10025946A1 (de) | 2000-05-26 | 2001-11-29 | Gruenenthal Gmbh | Wirkstoffkombination |
| WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| ATE345112T1 (de) | 2001-05-11 | 2006-12-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
| ATE493130T1 (de) * | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
| US7842307B2 (en) * | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| US20030068375A1 (en) * | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| EP1450824A4 (en) | 2001-11-02 | 2005-09-28 | Elan Corp Plc | PHARMACEUTICAL COMPOSITION |
| US6863901B2 (en) | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
| KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
| RU2273473C2 (ru) * | 2002-02-07 | 2006-04-10 | Фармация Корпорейшн | Фармацевтическая таблетка |
| US6855735B2 (en) | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
| US20050245556A1 (en) | 2002-04-05 | 2005-11-03 | Bianca Brogmann | Pharmaceutical preparation containing oxycodone and naloxone |
| US20050106249A1 (en) | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US8557291B2 (en) | 2002-07-05 | 2013-10-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
| CA2491572C (en) | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20040052844A1 (en) | 2002-09-16 | 2004-03-18 | Fang-Hsiung Hsiao | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins |
| EP2422773A3 (en) | 2002-09-20 | 2012-04-18 | Alpharma, Inc. | Sequestering subunit and related compositions and methods |
| CA2498798A1 (en) | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sustained-release opioid formulations and methods of use |
| CA2499994C (en) | 2002-09-23 | 2012-07-10 | Verion, Inc. | Abuse-resistant pharmaceutical compositions |
| CA2509259A1 (en) | 2003-01-23 | 2004-08-05 | Amorepacific Corporation | Sustained-release preparations and method for producing the same |
| US10172810B2 (en) | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
| ATE454169T1 (de) | 2003-03-13 | 2010-01-15 | Controlled Chemicals Inc | Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer |
| EP1782834A3 (en) | 2003-03-13 | 2007-08-01 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower abuse potential and extended duration of action |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| JP5501553B2 (ja) | 2003-04-21 | 2014-05-21 | ユーロ−セルティーク エス．エイ． | 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程 |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US20090304793A1 (en) | 2003-09-22 | 2009-12-10 | Alpharma, Inc. | Sustained release opioid formulations and methods of use |
| CN102697704A (zh) | 2003-09-26 | 2012-10-03 | 阿尔扎公司 | 阿片类与非阿片类镇痛药的控释制剂 |
| MXPA06003619A (es) | 2003-09-30 | 2008-01-14 | New River Pharmaceuticals Inc | Composiciones farmaceuticas para prevencion de sobredosis o abuso. |
| CA2541371C (en) | 2003-10-03 | 2014-12-16 | Atul M. Mehta | Extended release formulations of opioids and method of use thereof |
| HUP0303382A2 (hu) | 2003-10-10 | 2005-08-29 | EGIS Gyógyszergyár Rt. | Venlafaxin-hidroklorid-tartalmú pelletek |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| CN100491423C (zh) | 2003-12-15 | 2009-05-27 | 科学与工业研究委员会 | pH敏感性聚合物及其制备方法 |
| US20050165038A1 (en) | 2004-01-22 | 2005-07-28 | Maxwell Gordon | Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects |
| US20060024361A1 (en) | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
| US20070009589A1 (en) | 2005-07-07 | 2007-01-11 | Kandarapu Raghupathi | Extended release compositions |
| WO2008134071A1 (en) | 2007-04-26 | 2008-11-06 | Theraquest Biosciences, Inc. | Multimodal abuse resistant extended release formulations |
| US20090317355A1 (en) | 2006-01-21 | 2009-12-24 | Abbott Gmbh & Co. Kg, | Abuse resistant melt extruded formulation having reduced alcohol interaction |
| US20090022798A1 (en) * | 2007-07-20 | 2009-01-22 | Abbott Gmbh & Co. Kg | Formulations of nonopioid and confined opioid analgesics |
| ZA200807571B (en) | 2006-03-01 | 2009-08-26 | Ethypharm Sa | Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion |
| US20070212414A1 (en) | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
| US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| EP2484346B1 (en) | 2006-06-19 | 2017-02-22 | Alpharma Pharmaceuticals LLC | Pharmaceutical compositions |
| CA2659122C (en) | 2006-08-04 | 2016-08-23 | Ethypharm | Granule and orally disintegrating tablet comprising oxycodone |
| AU2007280471B2 (en) | 2006-08-04 | 2012-10-18 | Ethypharm | Multilayer orally disintegrating tablet |
| WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| US8445018B2 (en) * | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| US8187636B2 (en) | 2006-09-25 | 2012-05-29 | Atlantic Pharmaceuticals, Inc. | Dosage forms for tamper prone therapeutic agents |
| MX336789B (es) | 2007-08-13 | 2016-02-02 | Inspirion Delivery Technologies Llc | Farmacos resistentes al abuso, metodo de uso y metodo de fabricacion. |
| MX2010003032A (es) | 2007-09-21 | 2010-04-09 | Evonik R Hm Gmbh | Composicion farmaceutica opioide de liberacion controlada ph dependiente con resistencia contra la influencia del etanol. |
| US20090110724A1 (en) * | 2007-10-31 | 2009-04-30 | Everett Laboratories, Inc. | Compositions and methods for treatment of pain |
| EP2057984B1 (de) | 2007-11-09 | 2010-01-20 | Acino Pharma AG | Retardtabletten mit Hydromorphon |
| CN102014877B (zh) * | 2008-01-25 | 2017-06-06 | 格吕伦塔尔有限公司 | 药物剂型 |
| GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| US20110237614A1 (en) | 2008-09-16 | 2011-09-29 | Nektar Therapeutics | Pegylated Opioids with Low Potential for Abuse |
| WO2010044842A1 (en) * | 2008-10-16 | 2010-04-22 | University Of Tennessee Research Foundation | Tamper resistant oral dosage forms containing an embolizing agent |
| FR2949062B1 (fr) * | 2009-08-12 | 2011-09-02 | Debregeas Et Associes Pharma | Nouvelles formulations pharmaceutiques contre le mesusage des medicaments |
| US9211292B2 (en) | 2010-04-21 | 2015-12-15 | Alitair Pharmaceuticals Inc | Preventing or reducing drug abuse and overdose events |
| WO2012061779A1 (en) * | 2010-11-04 | 2012-05-10 | Abbott Gmbh & Co. Kg | Drug formulations |
| MX2013009492A (es) | 2011-02-17 | 2014-07-30 | Qrxpharma Ltd | Tecnologia para prevenir el abuso de formas de dosificacion solidas. |
| US20150224097A1 (en) | 2011-11-22 | 2015-08-13 | Watson Pharmaceuticals, Inc. | Immediate Release Abuse Deterrent Tablet |
| MX354677B (es) | 2012-03-02 | 2018-03-15 | Rhodes Pharmaceuticals Lp | Formulaciones de liberacion inmediata resistentes a la manipulacion. |
| US20140079740A1 (en) | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
| FR2999426B1 (fr) * | 2012-12-13 | 2015-01-02 | Flamel Tech Sa | Forme orale multiparticulaire a liberation immediate d'au moins un compose actif, comprenant des particules enrobees resistantes au broyage. |
| CA2817728A1 (en) * | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
| WO2015031410A1 (en) * | 2013-08-26 | 2015-03-05 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| US20150118300A1 (en) * | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| WO2015066172A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| WO2015120201A1 (en) | 2014-02-05 | 2015-08-13 | Kashiv Pharma, Llc | Abuse-resistant drug formulations with built-in overdose protection |
| WO2015158854A1 (en) | 2014-04-17 | 2015-10-22 | Develco Pharma Schweiz Ag | Oral dosage form of ketamine |
| DK3215147T3 (da) | 2014-11-04 | 2024-04-02 | Acadia Pharm Inc | Neurodæmpende norketamin-forbindelser og fremgangsmåder |
| WO2016094358A1 (en) | 2014-12-08 | 2016-06-16 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
-
2014
- 2014-07-17 US US14/333,986 patent/US20150118300A1/en not_active Abandoned
- 2014-07-17 WO PCT/US2014/047014 patent/WO2015065547A1/en not_active Ceased
- 2014-09-04 WO PCT/US2014/054061 patent/WO2015065586A1/en not_active Ceased
- 2014-09-04 US US14/477,354 patent/US20150118301A1/en not_active Abandoned
- 2014-09-12 US US14/484,793 patent/US20150118295A1/en not_active Abandoned
- 2014-10-29 MX MX2016005482A patent/MX384376B/es unknown
- 2014-10-29 JP JP2016552219A patent/JP6659925B2/ja active Active
- 2014-10-29 HK HK16112327.1A patent/HK1223856A1/zh unknown
- 2014-10-29 AU AU2014342412A patent/AU2014342412B2/en active Active
- 2014-10-29 KR KR1020167013870A patent/KR102363573B1/ko active Active
- 2014-10-29 PE PE2016000556A patent/PE20160606A1/es not_active Application Discontinuation
- 2014-10-29 US US15/032,658 patent/US20160250203A1/en not_active Abandoned
- 2014-10-29 CN CN201480059281.6A patent/CN105682647A/zh active Pending
- 2014-10-29 US US14/527,215 patent/US9707224B2/en active Active
- 2014-11-12 US US14/539,231 patent/US9757371B2/en active Active
-
2016
- 2016-04-22 ZA ZA2016/04451A patent/ZA201604451B/en unknown
- 2016-04-29 CL CL2016001031A patent/CL2016001031A1/es unknown
-
2018
- 2018-02-28 US US15/908,013 patent/US10568881B2/en active Active
-
2020
- 2020-01-23 US US16/751,043 patent/US11207318B2/en active Active
-
2021
- 2021-11-16 US US17/527,528 patent/US11844796B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535773A5 (enExample) | ||
| KR101840526B1 (ko) | 내변조성 제약 제제 | |
| JP5202522B2 (ja) | 制御性放出製剤および関連する方法 | |
| JP2017537168A5 (enExample) | ||
| ES2619574T3 (es) | Formulaciones de liberación inmediata resistentes a la manipulación | |
| CN100563656C (zh) | 抗破坏口服阿片样激动剂 | |
| ES2509497T3 (es) | Formulación de liberación controlada para evitar un uso indebido | |
| ES2625092T3 (es) | Formas de dosificación orales resistentes a la adicción y método de uso de las mismas | |
| RU2008151949A (ru) | Фармацевтические лекарственные формы и композиции фенилэфрина для абсорбции в ободочной кишке | |
| JP2015511953A5 (enExample) | ||
| RU2010129907A (ru) | Лекарственная форма с контролируемым высвобождением, предотвращающая неправильное употребление | |
| JP2018012711A5 (enExample) | ||
| JP2005508372A (ja) | 薬剤組成物 | |
| JP2014530185A5 (enExample) | ||
| MX2010008100A (es) | Formulacion extruida por fusion resistente al abuso que tiene interaccion reducida del alcohol. | |
| RU2011145432A (ru) | Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств | |
| JP2009538920A5 (enExample) | ||
| JP2016014040A5 (enExample) | ||
| JP2012526047A5 (enExample) | ||
| RU2011135568A (ru) | Защищенная от применения не по назначению экструдированная из расплава композиция с уменьшенным взаимодействием со спиртом | |
| BRPI0706753A2 (pt) | forma de dosagem e método para a distribuição de fármacos de abuso | |
| ES2685965T3 (es) | Composición farmacéutica disuasoria del abuso que comprende glucomanano de konjac | |
| CN101304752A (zh) | 防滥用的微粒口服药物形式 | |
| CA2709905A1 (en) | Abuse-resistant oxycodone composition | |
| WO2011125798A1 (ja) | 易服用性固形製剤 |